Study: Some women with early-stage breast cancer forego chemotherapy
Contents
At a glance | In-depth |
Findings | Limitations |
Clinical trials | Resources |
Questions for your doctor |
STUDY AT A GLANCE
This study is about:
Tailoring breast cancer treatment for women with mid-range Oncotype DX recurrence scores.
Why is this study important?
About half of all breast cancer cases diagnosed in the United States are hormone receptor-positive and node-negative — fed by hormones but not yet spread to the . , chemotherapy after tumor surgery, can reduce risk of recurrence, and the risk of dying from breast cancer in certain patients. But chemotherapy comes with side effects. Being able to determine which patients will or won’t receive benefit from chemotherapy is goal of prognostic tests such as Oncotype DX, Mammoprint, and others. XRAYS reviewed an earlier study by the same group of researchers that supported the clinical validity of Oncotype DX to identify patients who may be safely spared . The TAILORx trial is a continuation of this research and asks whether some patients receive unnecessary chemotherapy.
Study findings:
For women with hormone receptor-positive, , node-negative breast cancer
- Overall, women with Oncotype DX recurrence scores of 11-25 did as well on endocrine (hormonal) therapy alone as those given hormonal therapy plus chemotherapy.
- Women age 50 or younger with Oncotype DX recurrence scores of 16 to 25 who received plus hormonal therapy had lower rates of distant recurrence than those who received hormonal therapy alone.
What does this mean for me?
This clinical trial suggests that women with intermediate, mid-range Oncotype DX scores (11-25) do not benefit from . However, younger women (50 and under) with higher mid-range scores (16-25) may still benefit from . There is a point on the recurrence scale at which chemotherapy is beneficial, but that point is not yet certain. Your doctor may use other factors to decide which treatment is right for you.
Posted 7/20/18
Share your thoughts on this XRAYS article by taking our brief survey
Reference
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin , Keane MM, Gomez Moreno HL,Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg Abrams J, Sledge GW, et al. " Guided by a 21-Gene Expression Assay in Breast Cancer." New England J Med. 2018. 379(2):111-121.
Disclosure
FORCE receives funding from industry sponsors, including companies that manufacture cancer drugs, tests and devices. All XRAYS articles are written independently of any sponsor and are reviewed by members of our Scientific Advisory Board prior to publication to assure scientific integrity.
This article is relevant for:
People with node-negative, ER-positive breast cancer
This article is also relevant for:
men with breast cancer
people with ER/PR + cancer
people with a genetic mutation linked to cancer risk
people with breast cancer
Be part of XRAY:
IN-DEPTH REVIEW OF RESEARCH
Study background:
Oncotype DX is a test to predict whether chemotherapy will benefit a patient with hormone receptor-positive breast cancer. Recurrence scores are based on RNA expression of 21 genes. Recurrence scores range from 0 to 100. Scores of 31 and higher (or 26 and higher in some studies) are associated with chemotherapy benefit. Low recurrence scores (0-10) are associated with a very low risk of recurrence that chemotherapy is not likely to lower any further. While many experts recommend the use of the Oncotype DX tumor test as a predictor of recurrence and to guide chemotherapy recommendations, it was uncertain whether those who had mid-range recurrence scores would benefit from .
Researchers of this study wanted to know:
Whether they could further tailor treatment of hormone receptor-positive breast cancer for patients with mid-range Oncotype DX recurrence scores.
Study design:
The phase III, study enrolled women who were 18 to 75 years of age, had hormone receptor-positive, , axillary node-negative breast cancer who met National Comprehensive Cancer Network guidelines for the consideration of .
10,273 women registered for the study between October 6, 2010, and April 7, 2016.
There were 9,716 patients with follow-up information who were assigned therapy based on their Oncotype DX recurrence score:
- 6,711 (69%) had an Oncotype DX recurrence score of 11-25 and were randomly assigned to receive either endocrine therapy alone or endocrine therapy plus chemotherapy.
- 1,619 (17%) had an Oncotype DX recurrence score of 10 or lower and were assigned to receive endocrine therapy alone.
- 1,389 (14%) had an Oncotype DX recurrence score of 26 or higher and were assigned to receive chemotherapy plus endocrine therapy.
Median length of endocrine therapy was 5.4 years. The most common chemotherapy regimens among patients were docetaxel-cyclophosphamide (56%) and anthracycline-containing regimens. Hormonal therapies among postmenopausal women most commonly included an aromatase inhibitor (91%) and among premenopausal women either tamoxifen alone or tamoxifen followed by an aromatase inhibitor (78%). Suppression of ovarian function was used in 13% of premenopausal women.
Study findings:
Results of the TAILORx trial were presented on June 3, 2018, at the annual American Society of Clinical Oncology meeting in Chicago, Illinois and published in the New England Journal of Medicine.
- In patients with Oncotype DX recurrence scores ranging from 11 to 25, chemotherapy did not improve invasive disease-free survival (iDFS) when added to endocrine therapy.
- For endocrine therapy alone versus endocrine therapy plus chemotherapy:
- Nine-year iDFS rates were 83.3% and 84.3%.
- Freedom from recurrence of breast cancer at a distant site were 92.2% and 92.9%.
- Freedom from recurrence of breast cancer at a distant or local-regional site were 93.9% and 93.8%.
- Overall survival was 93.9% and 93.8% respectively.
- For endocrine therapy alone versus endocrine therapy plus chemotherapy:
- Women with Oncotype DX scores of 26 or higher had poorer outcomes with higher with higher even rates despite the addition of chemotherapy to endocrine therapy.
- Younger women (50 years or under) with a recurrence score of 16 to 25 saw some benefit with (slightly less than half of women in this age group had scores in this range).
- Women 50 or younger with recurrence scores of 16 to 20 who had had fewer distant recurrences.
- Women 50 or younger with recurrence scores of 21 to 25 who received had 7% fewer distant recurrences.
Limitations:
While chemotherapy had some benefit for women 50 years of age or younger with recurrence scores of 16 to 25, it is not clear why. It is possible that this observation is due a lowering of from chemo-induced menopause, but the researchers did not collect data on that. It remains unclear whether similar benefits could be achieved with ovarian suppression coupled with an aromatase inhibitor for these women.
Conclusions:
In the early 2000s, most patients with breast cancer who were hormone receptor-positive and node-negative received chemotherapy, but most did not benefit from it. The results of the TAILORx trail, the largest breast cancer treatment trial ever conducted, suggest that the Oncotype DX tumor test could identify up to 85% of women with early breast cancer who can forego , especially women older than 50 with a recurrence score of 25 or less and women 50 years of age or younger with a recurrence score of 15 or less. This trial, as well as other smaller trials, have generated new data that can guide use for patients. More studies are needed to clarify those women who need more of some therapies and less of other therapies.
Posted 7/20/18
Share your thoughts on this XRAYS article by taking our brief survey.
TNational Comprehensive Cancer Network (NCCN) guidelines recommend the following for tumor testing in , , ER-positive breast cancer:
Premenopausal women:
Oncotype Dx testing and the following treatments are recommended:
- No positive and tumors greater than 0.5 cm:
- For people with an Oncotype Dx recurrence score of 15 or lower:
- Recommend hormone therapy.
- Consider medications to suppress ovaries.
- Consider 3-5 years of bisphosphonate therapy
- For people with an Oncotype Dx recurrence score of 16-25:
- Recommend either hormone therapy plus medications to suppress ovaries or chemotherapy followed by hormone therapy.
- Consider 3-5 years of bisphosphonate therapy.
- For people with an Oncotype Dx recurrence score of 26 or higher:
- Recommend chemotherapy followed by hormone therapy
- Consider 3-5 years of bisphosphonate therapy
- For people with an Oncotype Dx recurrence score of 15 or lower:
- Micrometastasis to of 2 mm or smaller or 1-3 positive lymph nodes:
- Consider Oncotype Dx testing if a candidate for chemotherapy.
- Recommend either hormone therapy plus medications to suppress ovaries or chemotherapy followed by hormone therapy.
- Consider 3-5 years of bisphosphonate therapy.
The NCCN notes that data are limited about the use of Oncotype Dx in men. Available data suggest that the test provides prognostic information for men.
Updated: 11/13/2023
- What are the side effects of chemotherapy?
- Will chemotherapy lower my risk for a recurrence?
- Is it possible that I can be treated with endocrine therapy alone and forego chemotherapy?
- Are there any other tests that may help determine the best treatment for me?
The following are studies enrolling people with early ER-positive, breast cancer.
- NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (FLEX). The FLEX Registry is a large-scale, population based, registry. All patients with I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry.
- NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE). This study is looking at drug called (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen is a type of hormone therapy that blocks the body's natural from binding to cancer cells.
- NCT04584255: Treating HER2-Negative Breast Cancer with a () and (Dostarlimab) in People with a or Mutation. This study will look at how well the drugs (a ) and Dostarlimab (an ) treat breast cancer in people with an inherited , or mutation.
- NCT03749421: Prosigna Assay on Clinical Decision-making in Women With HR+/Her2- Breast Cancer. This research study is evaluating a genomic analysis called Predictor Analysis of Microarray 50 (PAM50, by Prosigna®) as a tool to possibly guide the participant and the treating physician to choose the most personalized pre-operative treatment for breast cancer.
- NCT04567420: DNA-Guided Second Line Therapy For High Residual Risk, II-III, Hormone Receptor Positive, Negative Breast Cancer. This study will monitor people with , high-risk breast cancer for possible recurrence using a test called circulating tumor (). People who test positive for but who have no other signs of recurrence, will receive either the drugs palbociclib combined with fulvestrant or standard-of-care hormone therapy.
-
NCT04852887: De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA). This study evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
A number of other clinical trials for patients with breast cancer can be found here.
Updated: 02/01/2024
The following organizations offer peer support services for people with, or at high risk for breast cancer:
- FORCE peer support:
- Our Message Boards allow people to connect with others who share their situation. Once you register, you can post on the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- Our Peer Navigation Program will match you with a volunteer who shares your mutation and situation.
- Connect online with our Private Facebook Group.
- Join our virtual and in-person support meetings.
- Other organizations that offer breast cancer support:
Updated: 05/07/2024
Who covered this study?
National Cancer Institute
Tailorx trial finds most women with early breast cancer do not benefit from chemotherapy This article rates 5.0 out of 5 stars
Genome Web
Fewer breast cancer patients benefit from chemo, TAILORx study with Oncotype DX finds This article rates 4.5 out of 5 stars
US News and World Report
Breaking down a groundbreaking breast cancer trial This article rates 4.5 out of 5 stars
The Wire
Many women with breast cancer may not need chemo, but beware misleading headlines This article rates 0.5 out of 5 stars